Regenxbio reports Q1 EPS 12c vs. ($1.38) last year

Reports Q1 revenue $89M vs. $115.6M last year. “We have made tremendous progress towards delivering multiple commercial gene therapies, starting this year,” said Curran Simpson, President and Chief Executive Officer of REGENXBIO (RGNX). “Each of our late-stage assets is demonstrating differentiation against standard of care or available treatments, giving us a pipeline of potential first- or best-in-class gene therapies for rare and retinal diseases. With advanced clinical programs, commercial-ready manufacturing in-house at our Rockville, MD headquarters, and a strong balance sheet, REGENXBIO is well-equipped to deliver potentially transformative gene therapies to patients in need.”